sFlt- 1, PIGF, and Niacin Levels in Women With Premature Ovarian Insufficiency

Premature Ovarian Insufficiency Clinical Trial

— POI&niacin  

Official title:

Soluble Fms-like Tyrosine Kinase-1, Proangiogenic Protein Placental Growth Factor, and Niacin Levels in Women With Premature Ovarian Insufficiency

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04641624
• Other study ID #: CengizGWCH11
• Status: Completed
• Start date: November 20, 2020
• Est. completion date: August 30, 2021

Study information

• Verified date: August 2021
• Source: Cengiz Gokcek Women's and Children's Hospital
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Aim: To evaluate serum soluble fms-like tyrosine kinase-1, proangiogenic protein placental growth factor, and niacin levels in women with premature ovarian insufficiency (POI) and to compare the results with those of healthy subjects.

Methods: This prospective study will be included 45 women with idiopathic premature ovarian insufficiency and 45 controls. The blood for analysis will be obtained at the early follicular phase of the menstrual cycle and serum soluble fms-like tyrosine kinase-1, proangiogenic protein placental growth factor, and niacin levels will be measured using a commercially available ELISA kit.

Description:

This will be an observational prospective cohort study conducted at Obstetrics and Gynecology Department of Cengiz Gokcek Obstetrics and Children's Hospital between November 2020 and April 2021. The investigators will be recruited 45 subjects with idiopathic POI, and 45 healthy patients were selected for the control group. All patients will be given their oral and written informed consent before their inclusion in the study. The protocol was approved by the Ethics Committee for Clinical Research of Gaziantep University (Reference number: 2020/320). The study strictly will be adhered to the principles of the Declaration of Helsinki.

Women between the ages of 18-39 will be included. A volunteer group of healthy women who will be visited the gynecology clinic for routine examinations and women who will be admitted for pre-pregnancy tests will be invited randomly to this research as a control group. Healthy women, who will be returned during their early follicular phase of the menstrual cycle, will be recruited as the control group subjects. The exclusion criteria will be as follows: women with evidence for karyotypic, metabolic, toxic, or iatrogenic cause of the ovarian insufficiency and any women who use any medication for POI treatment. At enrollment, for both groups, the investigators will be collected data about age, height, weight, BMI, age of menarche, obstetrics history, history of smoking, regular exercise and family history of POI. At enrolment, all patients will be underwent vaginal ultrasonography for the assessment of antral follicle count (AFC) and venous blood sample from the antecubital veins for measuring serum concentration of soluble fms-like tyrosine kinase-1, proangiogenic protein placental growth factor, and niacin, Follicle-stimulating hormone (FSH), E2, anti-mullerian hormone (AMH) and complete blood count (CBC). In control subjects venous blood samples and AFC will be collected during the early follicular phase of the menstrual cycle. The serum samples will be stored in aliquots at -80°C prior to the analyses of sFlt- 1, PIGF, and niacin. The serum soluble fms-like tyrosine kinase-1, proangiogenic protein placental growth factor, and niacin level will be measured using a commercially available enzyme-linked immunosorbent assay (ELISA) kit. Then, this study will be determined maternal serum soluble fms-like tyrosine kinase-1, proangiogenic protein placental growth factor, and niacin levels in women with POI (n=45) compared to those of volunteer healthy women (n=45). Then, these three markers levels will be compared in both group.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 90
• Est. completion date: August 30, 2021
• Est. primary completion date: June 30, 2021
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Female
• Age group: 18 Years to 39 Years

Eligibility

Inclusion Criteria:

• women with POI

• Healthy women

Exclusion Criteria:

1. women with any systemic condition (such as chronic hypertension, renal disease)

2. history of using any medication

3. drug user

4. history/presence of malignancy

5. history of Radiotherapy/chemotherapy

6. polycystic ovary syndrome

7. women who had any other acute/chronic infection or fever

8. Patients whose chromosome analysis result is not normal

9. history of ovarian surgery

10. Ovarian cysts/mass

11. pregnancy

12. lactation

Related Conditions & MeSH terms

• Menopause, Premature
• Premature Birth
• Premature Ovarian Insufficiency
• Primary Ovarian Insufficiency

Intervention

Other:
• ultrasound assessment
soluble fms-like tyrosine kinase-1, proangiogenic protein placental growth factor, and niacin measurementswith a commercially available enzyme-linked immunosorbent assay (ELISA) kit.

Locations

Country	Name	City	State
Turkey	Cengiz Gokcek Women's and Child's hospital	Gaziantep

Sponsors (1)

Lead Sponsor	Collaborator
Cengiz Gokcek Women's and Children's Hospital

Country where clinical trial is conducted

Turkey, 

References & Publications (4)

European Society for Human Reproduction and Embryology (ESHRE) Guideline Group on POI, Webber L, Davies M, Anderson R, Bartlett J, Braat D, Cartwright B, Cifkova R, de Muinck Keizer-Schrama S, Hogervorst E, Janse F, Liao L, Vlaisavljevic V, Zillikens C, V — View Citation

Maclaran K, Horner E, Panay N. Premature ovarian failure: long-term sequelae. Menopause Int. 2010 Mar;16(1):38-41. doi: 10.1258/mi.2010.010014. Review. — View Citation

Taraseviciene V, Grybauskiene R, Maciuleviciene R. sFlt-1, PlGF, sFlt-1/PlGF ratio and uterine artery Doppler for preeclampsia diagnostics. Medicina (Kaunas). 2016;52(6):349-353. doi: 10.1016/j.medici.2016.11.008. Epub 2016 Nov 29. — View Citation

Wang S, Sun M, Yu L, Wang Y, Yao Y, Wang D. Niacin Inhibits Apoptosis and Rescues Premature Ovarian Failure. Cell Physiol Biochem. 2018;50(6):2060-2070. doi: 10.1159/000495051. Epub 2018 Nov 9. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	sFlt- 1 levels	The primary outcome measure in this analysis will compare sFlt- 1 levels in the idiopathic POI group and control group.	1 week
Primary	PIGF levels	The primary outcome measure in this analysis will compare PIGF levels in the idiopathic POI group and control group.	1 week
Primary	niacin levels	The primary outcome measure in this analysis will compare niacin levels in the idiopathic POI group and control group.	1 week